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We have obtained and characterized 11 monoclonal antibodies (mAbs) specific for different domains of human tenascin (TN). Five of these mAbs 
reacted with epitopes contained in the TN area that undergoes alternative splicing and are thus able to recognize specific TN isoforms. These mAbs 
are a useful tool to study the expression and distribution of TN and its different isoforms in normal and pathological tissues. 
Tenascin; Monoclonal antibody 
1. INTRODUCTION 
Tenascin (TN) is a polymorphic high-molecular-mass 
extracellular matrix glycoprotein composed of six simi- 
lar subunits joined together at their aminoterminal by 
disulfide bonds [14]. The sequence of cDNA clones 
coding for the complete human TN molecule has been 
reported [5,6]. The deduced amino acid sequence shows 
that TN is a multidomain protein made up of 14.5 epi- 
dermal growth factor (EGF)-like repeats, 15 units simi- 
lar to fibronectin (FN) type three homology repeats and 
a C-terminal globular domain similar to /I and y chains 
of fibrinogen (see Fig. 1). According to a recent paper 
[7], a fibronectin type three repeat not previously ob- 
served is present in human TN between the B and the 
C repeats in the splicing area. 
neoexpression or dramatically increased expression has 
been documented in a variety of tumors [9-151. MAbs 
to TN have been employed as in vivo probes for radio- 
isotopic detection and radiotherapy of brain tumors 
[l&18]. 
More recently, Oyama et al. [19] and Borsi et al. [20] 
have demonstrated that in lung cancer and in invasive 
breast carcinoma the relative amount of the larger TN 
isoform is higher than in normal tissues. These observa- 
tions suggest that mAbs reacting with epitopes localized 
within the splicing area may be useful reagents for clin- 
ical applications. 
Recent works have described different TN isoforms 
generated by alternative splicing pattern of pre-mRNA 
[8] in which a group of 7 FN-like repeats are included 
or omitted. Moreover, it has been shown that up to 
eight different mRNA forms, containing different num- 
bers of FN-like repeats of the splicing area, may be 
generated by various splicing patterns of pre-mRNA in 
human cell lines in vitro [6,7]. TN displays a restricted 
distribution in normal adult tissues and its expression 
is related to morphogenetic events and embryo develop- 
ment. In fact, TN is transiently expressed in many devel- 
oping organs and has been proposed as a possible mod- 
ulator of epithelial-mesenchymal nd neuron-glial in- 
teractions during organogenesis. Moreover, transient 
expression of TN is also found in healing wounds and 
The aim of the present study was to prepare and 
characterize mAbs specific for different TN isoforms. 
We have obtained 11 monoclonal antibodies specific for 
human TN and we have demonstrated that 5 of them 
react with different epitopes localized in different type 
III repeats of the splicing area. 
2. MATERIALS AND METHODS 
2.1. Cell lines and monoclonal antibodies (mAbs) 
SK-MEL-28 human melanoma nd WI38 normal human fibroblast 
cell lines were purchased from ATCC American Type Culture Collec- 
tion (Rockville, MD, USA). BHK cells transfected with three different 
TN cDNA constructs in the pNUT expression vector were a gift of 
Dr. H.P. Erickson [21]. Two clones, H x B.L and H x B.S produce the 
large and the small TN splice variants respectively (TN. large, 
TN . small), and the third (H x B egf) produces a truncated molecule 
that terminates after the 14th EGF-like repeat (TN. egf). Human 
embryonal skin fibroblasts were obtained from local source. Cells 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) con- 
taining 10% fetal calf serum (FCS), both obtained from Northumbria 
Biologicals Ltd. (Cramlington, UK). 
*Corresponding author. Fax: (39) (10) 352-855 or 352-999. 
The preparation and the partial characterization of the mAbs BC-2, 
BC-4 and BC-7 have already been reported [6,20]. The mAbs BC-5, 
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Fig. 1. Model of the domain structure of human TN subunit. The ovals and the squares represent he EGF-like and FN-like repeats, respectively. 
The globular N-terminal and the fibrinogen-like C-terminal domains are also represented. The FN-like repeats Al to D whose expression is 
regulated by the alternative splicing of the pre-mRNA are shaded. The upper part of the figure also shows the TN-/I-galactosidase fusion proteins 
or other recombinant proteins used to localize the epitopes of the mAbs described within the TN molecule. The brackets in the lower part show 
the shortest sequence in which each epitope was locahxed. 
a-A2 and BC-6 were obtained by immunizing mice as previously 
reported [22] with TN puritied from the conditioned medium of SK- 
MEL-28 cell line. 
The mAbs lOOEB2 and 143AFl were obtained by immunizing mice 
with TN purified from the conditioned medium of human embryonal 
fibroblasts and the partial characterization of 100 EB2 has been re- 
ported [23]. 
The mAbs a-A3 and a-D were obtained by immunizing mice with 
/I-galactosidase TN fusion proteins containing the type III repeats A3 
and D, respectively (see Fig. l), using the expression vector &$ll. 
Immunofluorescence experiments were carried out as previously de- 
scribed [22]. The isotype of the mAbs was determined with the FITC 
(fluorescein isothiocyanate) method using a commercial kit purchased 
from Southern Biotechnology Associates Inc. (Birmingham, AL, 
USA). Results showed that all the mAbs are IgG,. 
TN was purified from conditioned medium of SK-MEL-28 human 
melanoma cell line using an immunoadsorbent prepared with the mAb 
BC-4 as already reported [24]. The same procedure was used to purify 
the large and small TN splice variants from the conditioned medium 
of transfected BHK cell lines. The amount of TN was evaluated using 
the absorption coefficient A,, (1 mg/ml, 1 cm) of 0.97 as reported by 
Erickson and Bourdon [3]. 
2.2. cDNA clones a&fusion proteins 
All the B-galactosidaseTN fusion proteins reported in this study 
were obtained using the expression vector jlgtll. The clones were 
obtained either by screening agtll cDNA libraries (1 A2; ptn 28; ptnl; 
ptn 29; ptn f5) or by inserting cDNAs obtained by polymerase chain 
reaction using appropriate oligonucleotides as primers @al; ila2; aa3; 
,&tq Lb; ;Ic; M). Immunoenzymatic reaction with mAbs was carried 
out using the ProtoBlot immunoscreening system kit purchased from 
Promega Biotech (Madison, WI). 
PCR reactions were performed for 35 cycles (1 min, 94°C; 1 min, 
48’C; 1 mitt, 68OC) in a final volume of 100 ml containing 50 mM KCl, 
10 mM Tris-Cl, pH 8.3, 1.5 mM MgC&, 0.01% (w/v) gelatin, 200 mM 
each dNTP, 100 pmol each oligo, 5 U of Taq DNA polymerase 
Table I 
Reaction of mAbs in immunoblotting with fusion or recombinant proteins 
mAbs TNegf lA2 ptn28 TNfnl-5 aal La2 jla3 la4 ab ac ad ptn29 ptnF5 TNfn6-8 TNtbg TN. TN. 
small large 
BC-7 + + - - - - - - - - - - - + + 
BC-4 + - + - - - - - _ _ - _ - + + 
BC-5 rt - + - - + + 
1OOEB; - - - + - - - - - - - - - + + 
BC_2 - - - - + - - + - - - - - - - - + 
a-A2 - - - - - + - - - _ - - - - - - + 
a-A3 - nd nd - - - + - - - - - - - - - + 
a-B - nd nd - _ - - - + - - + - - - - + 
a-D - nd nd - - - - - - - + + - - - - + 
BC-6 - nd nd nd - - - - - - - - + + - + + 
143AF, - - - - - - - - _ _ - + - + + 
N-end 1 79 cl87 620 1071 1162 1253 1344 1435 1526 1617 1244 1803 1708 1973 
C-end 619 >206 333 1070 1161 1252 1343 1434 1525 1616 1707 1890 1911 1972 2199 
Each mAb was tested in immunoblotting with the fusion or recombinant proteins whose sequence was known and with TN large and TN small 
which represent he two TN isoforms (280 kDa and 190 kDa, respectively) expressed in the transfected BHK cell lines. Results are reported as 
+ or - indicating positive or negative reaction. N-end and C-end represent amino- and carboxy terminal amino acid of each peptide according 
to the sequence reported by Siri et al. [6]. See also Fig. 1. 
“Data obtained with fusion proteins TNfnl-3 and TNfn3-5 including the corresponding FN-like type III repeats [21], have shown that this mAb 
gives a negative reaction with the first and a positive reaction with the second protein (G. Briscoe and H.P. Erickson, personal communication). 
Thus the epitope recognized by this mAb can be located either in the repeat 4 or in the repeat 5. 
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Fig. 3. Localiiation of the epitopes recognized by the mAb X-2 using 
fusion proteins. On the left, a 418% SDS-PAGE gradient of total 
protein from E. coli infected with clones containing TN inserts or 
@I 1 vector as reported above each lane. ptnl contains the FN-like 
repeats A4 and nearly a half of each of the repeats A3 and B; &I and 
ila4 contain the repeats Al and A4, respectively. On the right, im- 
munoblot of an identical gel with the mAb BC-2. The values on the 
left indicate the molecular masses in kDa of the standards. 
teins each containing one single repeat of the splicing 
area, showed a strong reaction with repeat Al and a 
weak reaction with repeat A4 (Fig. 3). This result can 
be explained by the high percentage of similarity be- 
tween the two type III repeats Al and A4 (83%). More- 
over, we found a strong reaction with the fusion protein 
containing repeat A4 and nearly a half of each of the 
repeats A3 and B: this result suggests that in the case 
of the epitope contained in the repeat A4, a longer 
sequence is needed to give rise to an epitope with high 
affinity for the mAb BC-2. 
We have tested the mAbs in immunofluorescence or 
immunohistochemically on normal human fibroblasts 
in culture and on several human normal and pathologi- 
cal tissues according to the procedure described. 10 
mAbs reacted to different extents in this assay and only 
one, a-A3, did not show any reaction (data not shown). 
F~he~ore, some mAbs which reacted very strongly 
in immunoblotting showed a very weak reaction in im- 
munofluorescence xperiments (BC-7; BC-6). These 
data indicate that some epitopes could be masked in the 
tissues, This could be due to the conformation of the 
native TN molecule or to interactions of TN with other 
molecules which could cover some TN regions. The fact 
that the mAbs aA3, BC-7 and BC-6 reacted well in 
radioimmunoassay or ELISA experiments using puri- 
fied native TN (data not shown) reinforce the bypothe- 
sis that in tissues some epitopes could be masked be- 
cause of the interaction with other macromol~~es. 
I~unohistochemical data show a wide presence of 
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TN in human neoplastic tissues [I 1,12,14,15]. On the 
basis of these findings, mAbs specific for TN have en- 
joyed both diagnostic and therapeutic applications, and 
successful results have been obtained in glioblastoma 
treatment [16-l 81. It has recently been reported [20] that 
in invasive breast carcinomas the relative amount of TN 
mRNA which includes the alternatively spliced region 
is about 10 times higher than in the RNA from normal 
breast tissues. Moreover, we have recently observed 
that the high molecular mass TN isoform in glioma 
samples represents more than 90% of total TN (Zardi, 
in preparation), and a similar observation has been re- 
ported by Ventimiglia et al. [27] in human glioma cell 
lines. Given these results, a wider diagnostic and thera- 
peutic use of mAbs specific for the larger TN isoforms 
might be considered for gliomas or other solid tumors. 
Moreover, since TN functions and mechanisms that 
control its expression and splicing pattern are not en- 
tirely claded, these antibodies prove useful tools to 
contribute to pertinent studies. 
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